December 20th 2024
Jason M Pogue, PharmD, BCPS, BCIDP discusses the findings, pharmacokinetics, why ceftolozane-tazobactam may be the preferred choice for resistant infections, and more.
November 11th 2024
Carbapenem-resistant Enterobacteriaceae (CRE) May Soon Be Treatable
May 25th 2016Researchers from the department of pathology at the Beth Israel Deaconess Medical Center in Boston developed and validated a high-throughput screen (HTS) that could detect antimicrobial agents with the ability to restore carbapenem susceptibility to resistant strains, as well as those that target CRE directly.
Read More
FDA Advises Restricting Use of Fluoroquinolone Antibacterial Therapies
May 13th 2016For patients who suffer from certain uncomplicated infections such as, sinusitis, bronchitis, and uncomplicated urinary tract infections, the health risks associated with fluoroquinolone far outweigh the benefits.
Read More
New Therapeutic Option for the Treatment of Drug-resistant Bacteria
May 11th 2016Older antibiotic agents show decreased potency due to overuse and the subsequent emergence of drug-resistant bacteria. This antimicrobial resistance has been predicted to have enormous consequences for human health, necessitating the development of new agents in the ongoing war between humans and the germs that attack us.
Read More
Antibiotic Resistance is More Complex Than You Think
May 2nd 2016Adding to the troubling data worldwide on antibiotic resistance, researchers have found that even trace concentrations of antibiotics, such as those found in sewage, are sufficient for bacteria to maintain resistance to most broad-spectrum agents.
Read More
CDC Calls on Healthcare Professionals to Help Fight Hospital Acquired Infections
March 14th 2016US hospitals have made significant reductions in the incidence of hospital-acquired infections (HAIs) over the past decade, a new report from the Centers for Disease Control and Prevention (CDC) has revealed.
Read More